NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Price, News & Analysis $19.23 -0.30 (-1.54%) Closing price 04:00 PM EasternExtended Trading$19.24 +0.00 (+0.03%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Anika Therapeutics Stock (NASDAQ:ANIK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Anika Therapeutics alerts:Sign Up Key Stats Today's Range$18.90▼$19.3950-Day Range$18.07▼$22.0352-Week Range$8.67▼$22.88Volume126,202 shsAverage Volume113,209 shsMarket Capitalization$257.30 millionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingHold Company Overview Anika Therapeutics, Inc. is a medical technology company focused on joint preservation and orthopedic care. The company develops and commercializes products designed to relieve pain, restore mobility and support the repair or protection of damaged joints and tissues, with an emphasis on therapies based on hyaluronic acid and other regenerative technologies. Anika’s portfolio includes viscosupplementation products for osteoarthritis, including Orthovisc, Monovisc and Cingal. These injectable treatments are intended to supplement the natural synovial fluid in the knee and other joints. The company also offers products for sports medicine, soft-tissue repair and regenerative care, including Hyaloglide, an adhesion barrier used in tendon-repair procedures, along with other surgical and orthopedic solutions. Founded in 1983 and headquartered in Bedford, Massachusetts, Anika has built its business around the development and commercialization of hyaluronic-acid-based medical products. Its products are marketed in the United States and internationally through a combination of direct commercial activities and distribution partners, serving orthopedic surgeons, sports-medicine specialists and other healthcare providers.AI Generated. May Contain Errors. Read More Anika Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreANIK MarketRank™: Anika Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 414th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingHold Consensus RatingAnika Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnika Therapeutics has a consensus price target of $22.00, representing about 14.4% upside from its current price of $19.23.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Anika Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth107.14% Earnings GrowthEarnings for Anika Therapeutics are expected to grow by 107.14% in the coming year, from $0.14 to $0.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -71.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -71.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAnika Therapeutics has a PEG Ratio of 13.66. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anika Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.24% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 5.36.Change versus previous monthShort interest in Anika Therapeutics has recently increased by 10.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News SentimentN/A News SentimentAnika Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Anika Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $20,750.00 in company stock, which represents 0.0081% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,750.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.08% of the stock of Anika Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Anika Therapeutics' insider trading history. Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIK Stock News HeadlinesAnika (ANIK) Q2 2026 Earnings Call TranscriptAugust 8, 2026 | finance.yahoo.comAnika Therapeutics Lifts Outlook After Margin SurgeAugust 2, 2026 | tipranks.comThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40 trillion by fall. Servicing that debt now costs more than the entire defense budget, while inflation above 3.5% keeps eroding cash savings. Central banks are responding by buying gold at the fastest pace in decades. The U.S. Gold Bureau's complimentary guide covers IRA-eligible gold and silver options, secure storage, and a fast BuyBack Guarantee.October 8 at 1:00 AM | US Gold Bureau (Ad)Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher GuidanceAugust 2, 2026 | finance.yahoo.comThese 2 biotech stocks hit new 52-week highs today – and CORT clocked its best day in nearly 16 monthsJuly 30, 2026 | msn.comClarevia Ventures Welcomes Cheryl R. Blanchard, Ph.D., as Executive in ResidenceJuly 30, 2026 | finance.yahoo.comAnika Therapeutics Inc.: Anika Reports Second Quarter 2026 Financial ResultsJuly 29, 2026 | finanznachrichten.deAnika Therapeutics (ANIK) Q2 2026 EarningsJuly 29, 2026 | 247wallst.comSee More Headlines ANIK Stock Analysis - Frequently Asked Questions How have ANIK shares performed this year? Anika Therapeutics' stock was trading at $9.61 on January 1st, 2026. Since then, ANIK shares have increased by 100.1% and is now trading at $19.23. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics Inc. (NASDAQ:ANIK) released its quarterly earnings results on Wednesday, July, 29th. The biotechnology company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.39. The biotechnology company earned $32.61 million during the quarter, compared to analysts' expectations of $29.21 million. Anika Therapeutics had a positive trailing twelve-month return on equity of 0.20% and a negative net margin of 3.14%. Read the conference call transcript. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings7/29/2026Today10/08/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ANIK's financial health is in the Green zone, according to TradeSmith. ANIK has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANIK CIK898437 Webwww.anika.com Phone(781) 457-9000Fax781-305-9720Employees235Year Founded1992Price Target and Rating Average Price Target for Anika Therapeutics$22.00 High Price Target$23.00 Low Price Target$21.00 Potential Upside/Downside+14.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E Ratio137.36 P/E Growth13.66Net Income-$10.88 million Net Margins-3.14% Pretax Margin-2.41% Return on Equity0.20% Return on Assets0.15% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio3.19 Sales & Book Value Annual Sales$112.82 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$9.95 per share Price / Book1.93Miscellaneous Outstanding Shares13,380,000Free Float11,766,000Market Cap$257.30 million OptionableOptionable Beta0.21 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ANIK) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...Market Savvy | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
